MTAP loss in gastrointestinal cancers is associated with CDKN2A deletion, poor prognosis in gastric carcinoma, and potential relevance for PRMT5-targeted therapy

Abstract Gastrointestinal cancers account for a substantial share of global cancer burden. We assessed the significance of MTAP loss across 1545 resected tumors (cholangiocarcinoma, esophageal and gastric adenocarcinoma, pancreatic ductal adenocarcinoma). MTAP protein was evaluated by immunohistoche...

תיאור מלא

מידע ביבליוגרפי

Principais autores:	Su Ir Lyu, Karl Knipper, Caroline Fretter, Eleni Tzitzili, Adrian Georg Simon, Hakan Alakus, Aylin Pamuk, Christiane J. Bruns, Thomas Schmidt, Felix C. Popp, Alexander Quaas
פורמט:	Artigo
שפה:	Inglês
יצא לאור:	Nature Portfolio 2026-05-01
סדרה:	Scientific Reports
נושאים:	MTAP-loss Esophageal cancer Gastric cancer Pancreatic cancer PRMT5-inhibitor
גישה מקוונת:	https://doi.org/10.1038/s41598-026-51370-9
תגים:	הוספת תג אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!